Structural basis of the multiple ligand binding mechanisms of the P2X1 receptor

被引:0
作者
Qiang, Yu-ting [1 ,2 ]
Wu, Peng-peng [3 ,4 ]
Liu, Xin [2 ,5 ]
Peng, Li [2 ]
Zhao, Li-ke [2 ]
Chen, Ya-ting [2 ,6 ]
Gao, Zhao-bing [2 ,3 ,4 ]
Zhao, Qiang [1 ,2 ,3 ,4 ,5 ,6 ]
Chen, Kun [2 ,3 ,4 ]
机构
[1] Guizhou Med Univ, Sch Pharm, Guiyang 550025, Guizhou, Peoples R China
[2] Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan 528400, Peoples R China
[3] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
[4] Univ Chinese Acad Sci, Beijing 100049, Peoples R China
[5] Southern Med Univ, Sch Pharmaceut Sci, Guangzhou 510515, Peoples R China
[6] Zunyi Med Univ, Sch Pharm, Zunyi 563006, Peoples R China
关键词
Structural biology; Ligand binding mode; Ion channel; Purinergic P2X1 receptor; P2X(1) RECEPTOR; ION-CHANNEL; ACTIVATION; PATHOPHYSIOLOGY; PHYSIOLOGY; ANALOGS; POTENT; NF449;
D O I
10.1038/s41401-025-01512-y
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
As important modulators of human purinergic signaling, P2X1 receptors form homotrimers to transport calcium, regulating multiple physiological processes, and are long regarded as promising therapeutic targets for male contraception and inflammation. However, the development of drugs that target the P2X1 receptor, such as the antagonist NF449, is greatly hindered by the unclear molecular mechanism of ligand binding modes and receptor activation. Here, we report the structures of the P2X1 receptor in complex with the endogenous agonist ATP or the competitive antagonist NF449. The P2X1 receptor displays distinct conformational features when bound to different types of compounds. Despite coupling to the agonist ATP, the receptor adopts a desensitized conformation that arrests the ions in the transmembrane (TM) domain, aligning with the nature of the high desensitization rates of the P2X1 receptor within the P2X family. Interestingly, the antagonist NF449 not only occupies the orthosteric pocket of ATP but also interacts with the dorsal fin, left flipper, and head domains, suggesting a unique binding mode to perform both orthosteric and allosteric mechanisms of NF449 inhibition. Intriguingly, a novel lipid binding site adjacent to the TM helices and lower body of P2X1, which is critical for receptor activation, is identified. Further functional assay results and structural alignments reveal the high conservation of this lipid binding site in P2X receptors, indicating important modulatory roles upon lipid binding. Taken together, these findings greatly increase our understanding of the ligand binding modes and multiple modulatory mechanisms of the P2X1 receptor and shed light on the further development of P2X1-selective antagonists.
引用
收藏
页码:2564 / 2573
页数:10
相关论文
共 40 条
[1]   The Intracellular Amino Terminus Plays a Dominant Role in Desensitization of ATP-gated P2X Receptor Ion Channels [J].
Allsopp, Rebecca C. ;
Evans, Richard J. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (52) :44691-44701
[2]   Perspective on the role of P2X-purinoceptor activation in human vas deferens contractility [J].
Amobi, Nnaemeka I. B. ;
Guillebaud, John ;
Smith, I. Christopher H. .
EXPERIMENTAL PHYSIOLOGY, 2012, 97 (05) :583-602
[3]   The P2X1 receptor as a therapeutic target [J].
Bennetts, Felix M. ;
Mobbs, Jesse, I ;
Ventura, Sabatino ;
Thal, David M. .
PURINERGIC SIGNALLING, 2022, 18 (04) :421-433
[4]   Post-translational regulation of P2X receptor channels: modulation by phospholipids [J].
Bernier, Louis-Philippe ;
Ase, Ariel R. ;
Seguela, Philippe .
FRONTIERS IN CELLULAR NEUROSCIENCE, 2013, 7
[5]   Pharmacological characterization of recombinant human and rat P2X receptor subtypes [J].
Bianchi, BR ;
Lynch, KJ ;
Touma, E ;
Niforatos, W ;
Burgard, EC ;
Alexander, KM ;
Park, HS ;
Yu, HX ;
Metzger, R ;
Kowaluk, E ;
Jarvis, MF ;
van Biesen, T .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 376 (1-2) :127-138
[6]   Actions of a series of PPADS analogs at P2X1 and P2X3 receptors [J].
Brown, SG ;
Kim, YC ;
Kim, SA ;
Jacobson, KA ;
Burnstock, G ;
King, BF .
DRUG DEVELOPMENT RESEARCH, 2001, 53 (04) :281-291
[7]   Pathophysiology and therapeutic potential of purinergic signaling [J].
Burnstock, G .
PHARMACOLOGICAL REVIEWS, 2006, 58 (01) :58-86
[8]   Physiology and pathophysiology of purinergic neurotransmission [J].
Burnstock, Geoffrey .
PHYSIOLOGICAL REVIEWS, 2007, 87 (02) :659-797
[9]   Purinergic Signaling and Blood Vessels in Health and Disease [J].
Burnstock, Geoffrey ;
Ralevic, Vera .
PHARMACOLOGICAL REVIEWS, 2014, 66 (01) :102-192
[10]   Purinergic Receptors and Pain [J].
Burnstock, Geoffrey .
CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (15) :1717-1735